TY  - JOUR
A1  - Heisig, Anne
A1  - Sörensen, Jan
A1  - Zimmermann, Stefanie-Yvonne
A1  - Schöning, Stefan
A1  - Schwabe, Dirk
A1  - Kvasnicka, Hans Michael
A1  - Schwentner, Raphaela
A1  - Hutter, Caroline
A1  - Lehrnbecher, Thomas
T1  - Vemurafenib in Langerhans cell histiocytosis : report of a pediatric patient and review of the literature
T2  - OncoTarget
N2  - Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem to cure the patients, and it is unknown, when and how to stop vemurafenib treatment. We present a girl with severe multisystem LCH who responded only to vemurafenib. After 8 months of treatment, vemurafenib was tapered and replaced by prednisone and vinblastine, a strategy which has not been described to date. Despite chemotherapy, early relapse occurred, but remission was achieved by re-institution of vemurafenib. Further investigation needs to address the optimal duration of vemurafenib therapy in LCH and whether and which chemotherapeutic regimen may prevent disease relapse after cessation of vemurafenib.
KW  - Langerhans cell histiocytosis
KW  - LCH
KW  - child
KW  - vemurafenib
KW  - BRAF
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/46579
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-465795
SN  - 1949-2553
N1  - All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
VL  - 9
IS  - 31
SP  - 22236
EP  - 22240
PB  - Impact Journals LLC
CY  - [s. l.]
ER  -